OR WAIT null SECS
The platform, developed by Vectron Biosolutions, will be used for BI’s in-house pipeline and for its outsourcing clients.
Boehringer Ingelheim (BI) announced on Sept. 1, 2015 that the company will use Vectron Biosolutions’ microbial expression technology platform for the production of proteins in its own pipeline, as well as for its contract manufacturing clients through its BioXcellence business.
BI made the decision to go with Vectron’s platform after the performance of a joint feasibility study, in which Vectron produced one of BI’s proteins of interest using Vectron’s proprietary expression vectors. After testing for yield and solubility, BI concluded the technology would be a good fit for its own in-house microbial production operations, as well as its outsourcing clients.